Mallinckrodt plc (“Mallinckrodt”) and Endo, Inc. (OTCQX: NDOI) (“Endo”) announce that they have entered into a definitive agreement to combine in a stock and cash transaction to create a global, scaled, diversified pharmaceuticals leader. “The combination of Mallinckrodt and Endo brings together two essential pharmaceuticals organizations to accelerate value creation for our shareholders, customers, employees, the patients we serve and our other stakeholders,” said Siggi Olafsson, President and Chief Executive Officer of Mallinckrodt. After cash consideration, Mallinckrodt shareholders will own 50.1% of the combined company on a pro forma basis, for an implied pro forma enterprise value of $6.7 billion.
Read the full article: Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader //
Source: https://www.prnewswire.com/news-releases/mallinckrodt-and-endo-to-combine-to-create-a-global-scaled-diversified-pharmaceuticals-leader-302400849.html